Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561242 | 0.91 | F10 (0.39) | F10KMT2AADRB2NPSR1ROCK2 | |
| SCHEMBL3565023 | 0.91 | F10 (0.43) | F10MEN1KMT2AEP300 | |
| SCHEMBL3574000 | 0.87 | F10 (0.42) | F10ROCK2EP300 | |
| SCHEMBL3565553 | 0.86 | F10 (0.41) | F10MEN1KMT2AEP300 | |
| SCHEMBL3569135 | 0.86 | F10 (0.38) | F10ROCK2 | |
| SCHEMBL3562898 | 0.85 | LMNA (0.43) | F10 | |
| SCHEMBL5815332 | 0.84 | MEN1 (0.39) | F10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3558910 | 0.84 | F10 (0.42) | F10MEN1POLBKMT2ANPSR1 | |
| SCHEMBL3568352 | 0.83 | F10 (0.42) | F10MEN1KMT2AADRB2NPSR1 | |
| SCHEMBL3564016 | 0.83 | F10 (0.41) | F10MEN1KMT2AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | F10 9/4885MEN1 2311/4885POLB 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.